CoChat

Chronic social stress-induced hyperglycemia in mice couples individual stress susceptibility to impaired spatial memory

Open access
van der Kooij, Michael A., Jene, Tanja, Treccani, Giulia, Miederer, Isabelle, Hasch, Annika, Voelxen, Nadine, Walenta, Stefan, Müller, Marianne B. · 2018 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

Significance: Stress-associated mental disorders and diabetes pose an enormous socio-economic burden. Glucose dysregulation occurs with both psychosocial and metabolic stress. While cognitive impairments are common in metabolic disorders such as diabetes and are accompanied by hyperglycemia, a causal role for glucose has not been established. We show that chronic social defeat (CSD) stress induces lasting peripheral and central hyperglycemia and impaired glucose metabolism in a subgroup of mice. Animals exhibiting hyperglycemia early post-CSD display spatial memory impairments that can be rescued by the antidiabetic empagliflozin. We demonstrate that individual stress vulnerability to glucose homeostasis can be identified early after insult and that stress-induced hyperglycemia directly impinges on cognitive integrity. Our findings further bridge the gap between stress-related pathologies and metabolic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1804412115

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. CSD causes hyperglycemia, hypercortisolemia, adrenal hyperplasia, and hyperphagia. (A) Blood glucose levels in stressed mice were increased at 2 d post-CSD [interaction: F(2,90) = 7.65, P < 0.001, n = 23 or 24 per group, comparing days 4–12 (t = 3.12, df = 90, P < 0.01) and days 8–12 (t = 3.27, df = 90, P < 0.01)]. (B) Morning levels of blood plasma corticosterone were increased in CSD-exposed animals at 2 d post-CSD (t = 2.62, df = 35, P = 0.013, n = 18 or 19 per group). (C and D) CSD-exposed animals exhibited increased adrenal weight (t = 7.02, df = 18, P < 0.001, n = 10 per group) (C) and hyperphagia throughout CSD (t = 3.80, df = 10, P = 0.004) (D). (E) Blood plasma leptin levels taken 1 wk post-CSD did not differ between CSD-exposed and control (CTRL) mice (t = 0.55, df = 28, P = 0.59, n = 14–16 per group). Data are presented as mean + SEM; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test in B–D and two-way repeated-measures ANOVA with Bonferroni’s posttest in A.
Fig. 1. CSD causes hyperglycemia, hypercortisolemia, adrenal hyperplasia, and hyperphagia. (A) Blood glucose levels in stressed mice were increased at 2 d post-CSD [interaction: F(2,90) = 7.65, P < 0.001, n = 23 or 24 per group, comparing days 4–12 (t = 3.12, df = 90, P < 0.01) and days 8–12 (t = 3.27, df = 90, P < 0.01)]. (B) Morning levels of blood plasma corticosterone were increased in CSD-exposed animals at 2 d post-CSD (t = 2.62, df = 35, P = 0.013, n = 18 or 19 per group). (C and D) CSD-exposed animals exhibited increased adrenal weight (t = 7.02, df = 18, P < 0.001, n = 10 per group) (C) and hyperphagia throughout CSD (t = 3.80, df = 10, P = 0.004) (D). (E) Blood plasma leptin levels taken 1 wk post-CSD did not differ between CSD-exposed and control (CTRL) mice (t = 0.55, df = 28, P = 0.59, n = 14–16 per group). Data are presented as mean + SEM; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test in B–D and two-way repeated-measures ANOVA with Bonferroni’s posttest in A.CC BY-NC-ND · PubMed Central
Fig. 2. CSD perturbs glucose metabolism and affects behavior. (A and B) Control (CTRL) mice readily explore a cylinder containing an unknown CD-1 mouse placed in the center of an open field arena, but CSD-exposed mice show less exploration [depicted by representative heat maps (A) and quantified (B): t = 2.85, df = 16, P = 0.012, n = 9 per group]. (C) Peripheral hyperglycemia develops post-CSD and lasts ∼2 wk before returning to baseline [time: F(4,72) = 2.81, P = 0.032; CSD: F(1,18) = 12.68, P = 0.002; interaction: F(4,72) = 8.53, P < 0.001, n = 10 per group]. Glucose levels differed at 1 wk (t = 5.44, df = 90, P < 0.001) and 2 wk (q = 4.56, df = 90, P < 0.001) post-CSD. Behavioral testing (except the CD-1 encounter) and the GTT took place during this hyperglycemic period. Long-term effects of CSD were measured by HbA1c 8 wk post-CSD. (D) In the GTT, CSD-exposed mice displayed delayed recovery from a glucose bolus (2 g/kg i.p.) [interaction: F(4,72) = 3.64, P = 0.009; time: F(4,72) = 49.91, P < 0.001; n = 10 per group with differences at 30 min (t = 4.13, df = 90, P < 0.001)]. (E) CSD-exposed mice exhibited increased immobility time in the forced swim test compared with control mice (t = 3.17, df = 19, P = 0.005, n = 9–12 per group). (F) Novel object preference was intact with no CSD effects [performance against chance for control mice (t = 6.28, df = 18, P < 0.001) and for CSD-exposed mice (t = 4.15, df = 18, P < 0.001); CSD (t = 0.64, df = 36, P = 0.52, n = 19 per group)]. (G and H) Control mice explored the novel (NEW) arm of the Y-maze more than the familiar (FAM) arm, but CSD-exposed mice did not display this preference [depicted by representative heat maps (G) and quantified (H): against chance for control mice: t = 5.79, df = 9, P < 0.001; for CSD-exposed mice: t = 0.06, df = 9, P = 0.95; CSD: t = 2.86, df = 18, P = 0.01, n = 10 per group]. (I) CD-1 exploration correlated positively with novel arm preference in the Y-maze; the regression line is shown with the 95% confidence interval (dotted lines) (r = 0.67, r2 = 0.45, P = 0.034). (J) Control mice displayed a preference for the replaced object in the object location task (t = 5.23, df = 14, P < 0.001), but this preference was not seen for CSD-exposed mice (t = 1.62, df = 12, P = 0.13). (K) HbA1c in the peripheral blood was increased for stressed mice 8 wk post-CSD (t = 3.96, df = 19, P < 0.001, n = 10 or 11 per group). Data are presented as mean + SEM; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test in B, E, F, H, and J; one-sample t test against chance in F and H; Pearson’s correlation coefficient in I; one-way repeated-measures ANOVA with Bonferroni’s posttest in C; or two-way repeated-measures ANOVA with Bonferroni’s posttest in D.
Fig. 2. CSD perturbs glucose metabolism and affects behavior. (A and B) Control (CTRL) mice readily explore a cylinder containing an unknown CD-1 mouse placed in the center of an open field arena, but CSD-exposed mice show less exploration [depicted by representative heat maps (A) and quantified (B): t = 2.85, df = 16, P = 0.012, n = 9 per group]. (C) Peripheral hyperglycemia develops post-CSD and lasts ∼2 wk before returning to baseline [time: F(4,72) = 2.81, P = 0.032; CSD: F(1,18) = 12.68, P = 0.002; interaction: F(4,72) = 8.53, P < 0.001, n = 10 per group]. Glucose levels differed at 1 wk (t = 5.44, df = 90, P < 0.001) and 2 wk (q = 4.56, df = 90, P < 0.001) post-CSD. Behavioral testing (except the CD-1 encounter) and the GTT took place during this hyperglycemic period. Long-term effects of CSD were measured by HbA1c 8 wk post-CSD. (D) In the GTT, CSD-exposed mice displayed delayed recovery from a glucose bolus (2 g/kg i.p.) [interaction: F(4,72) = 3.64, P = 0.009; time: F(4,72) = 49.91, P < 0.001; n = 10 per group with differences at 30 min (t = 4.13, df = 90, P < 0.001)]. (E) CSD-exposed mice exhibited increased immobility time in the forced swim test compared with control mice (t = 3.17, df = 19, P = 0.005, n = 9–12 per group). (F) Novel object preference was intact with no CSD effects [performance against chance for control mice (t = 6.28, df = 18, P < 0.001) and for CSD-exposed mice (t = 4.15, df = 18, P < 0.001); CSD (t = 0.64, df = 36, P = 0.52, n = 19 per group)]. (G and H) Control mice explored the novel (NEW) arm of the Y-maze more than the familiar (FAM) arm, but CSD-exposed mice did not display this preference [depicted by representative heat maps (G) and quantified (H): against chance for control mice: t = 5.79, df = 9, P < 0.001; for CSD-exposed mice: t = 0.06, df = 9, P = 0.95; CSD: t = 2.86, df = 18, P = 0.01, n = 10 per group]. (I) CD-1 exploration correlated positively with novel arm preference in the Y-maze; the regression line is shown with the 95% confidence interval (dotted lines) (r = 0.67, r2 = 0.45, P = 0.034). (J) Control mice displayed a preference for the replaced object in the object location task (t = 5.23, df = 14, P < 0.001), but this preference was not seen for CSD-exposed mice (t = 1.62, df = 12, P = 0.13). (K) HbA1c in the peripheral blood was increased for stressed mice 8 wk post-CSD (t = 3.96, df = 19, P < 0.001, n = 10 or 11 per group). Data are presented as mean + SEM; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test in B, E, F, H, and J; one-sample t test against chance in F and H; Pearson’s correlation coefficient in I; one-way repeated-measures ANOVA with Bonferroni’s posttest in C; or two-way repeated-measures ANOVA with Bonferroni’s posttest in D.CC BY-NC-ND · PubMed Central
Fig. 3. CSD induces cerebral hyperglycemia. (A) Brain glucose levels of CSD-exposed animals were increased compared with controls (CTRL) (t = 2.61, df = 10.47, P = 0.025, n = 10 per group). (B) Peripheral blood glucose levels correlated positively with cerebral glucose levels (r = 0.52, r2 = 0.27, P = 0.018). (C) The cerebral hyperglycemia also pertained to the hippocampus. (Top) H&E staining. (Middle and Bottom) Bioluminescent signal for control mice (Middle) and CSD-exposed mice (Bottom). (D) Quantification of hippocampal glucose (t = 2.53, df = 11.58, P = 0.027, n = 10 per group; white bar, control; black bar, CSD). (E) Hippocampal glucose correlated negatively with spatial memory performance (r = −0.47, r2 = 0.22, P = 0.037). (F) Glucose/saline was infused into the hippocampus, and mice were tested in the Y-maze. (G) Glucose-infused mice did not display a preference in novel arm exploration, unlike vehicle-infused mice (vehicle infusion: t = 3.93, df = 8, P = 0.004; glucose infusion: t = 0.40, df = 7, P = 0.70), and intrahippocampal glucose reduced novel arm preference compared with vehicle-treated control mice (t = 2.19, df = 15, P = 0.045, n = 8 or 9 per group). (H) Verification of the hippocampal injection. (Right) A representative image of the injection site (in blue). (Left) The corresponding Nissl-stained histological plate. Image courtesy of © 2004 Allen Institute for Brain Science. Allen Mouse Brain Atlas. Available from: http://mouse.brain-map.org/experiment/siv?id=100142143&imageId=102162210&imageType=atlas&initImage=atlas&showSubImage=y&contrast=0.5,0.5,0,255,4. Data are presented as mean + SEM; *P < 0.05, Student’s t test in A, D, and G with Pearson’s correlation coefficient in B and E. Regression lines are shown with the 95% confidence interval (dotted lines) in B and E.
Fig. 3. CSD induces cerebral hyperglycemia. (A) Brain glucose levels of CSD-exposed animals were increased compared with controls (CTRL) (t = 2.61, df = 10.47, P = 0.025, n = 10 per group). (B) Peripheral blood glucose levels correlated positively with cerebral glucose levels (r = 0.52, r2 = 0.27, P = 0.018). (C) The cerebral hyperglycemia also pertained to the hippocampus. (Top) H&E staining. (Middle and Bottom) Bioluminescent signal for control mice (Middle) and CSD-exposed mice (Bottom). (D) Quantification of hippocampal glucose (t = 2.53, df = 11.58, P = 0.027, n = 10 per group; white bar, control; black bar, CSD). (E) Hippocampal glucose correlated negatively with spatial memory performance (r = −0.47, r2 = 0.22, P = 0.037). (F) Glucose/saline was infused into the hippocampus, and mice were tested in the Y-maze. (G) Glucose-infused mice did not display a preference in novel arm exploration, unlike vehicle-infused mice (vehicle infusion: t = 3.93, df = 8, P = 0.004; glucose infusion: t = 0.40, df = 7, P = 0.70), and intrahippocampal glucose reduced novel arm preference compared with vehicle-treated control mice (t = 2.19, df = 15, P = 0.045, n = 8 or 9 per group). (H) Verification of the hippocampal injection. (Right) A representative image of the injection site (in blue). (Left) The corresponding Nissl-stained histological plate. Image courtesy of © 2004 Allen Institute for Brain Science. Allen Mouse Brain Atlas. Available from: http://mouse.brain-map.org/experiment/siv?id=100142143&imageId=102162210&imageType=atlas&initImage=atlas&showSubImage=y&contrast=0.5,0.5,0,255,4. Data are presented as mean + SEM; *P < 0.05, Student’s t test in A, D, and G with Pearson’s correlation coefficient in B and E. Regression lines are shown with the 95% confidence interval (dotted lines) in B and E.CC BY-NC-ND · PubMed Central
Fig. 4. CSD reduced cerebral glucose uptake and decreased hippocampal protein expression of GluT1. (A) 18F-FDG uptake in the whole brain was reduced in CSD-exposed mice compared with control mice as shown by PET scans obtained by overlay from the individual PET signals. (B and C) Results in A quantified for the whole brain (t = 2.50, df = 15, P = 0.025, n = 8 or 9 per group) (B) and for the hippocampus (t = 2.17, df = 15, P = 0.047, n = 8 or 9 per group) (C). (D–F) Hippocampal membrane protein levels were reduced for GluT1 (t = 2.45, df = 9.2, P = 0.036) (D) but not for GluT3 (t = 0.94, df = 15, P = 0.40) (E) or GluT4 (t = 0.66, df = 14, P = 0.52) (F). Data are presented as mean + SEM; *P < 0.05, Student’s t test in B–D.
Fig. 4. CSD reduced cerebral glucose uptake and decreased hippocampal protein expression of GluT1. (A) 18F-FDG uptake in the whole brain was reduced in CSD-exposed mice compared with control mice as shown by PET scans obtained by overlay from the individual PET signals. (B and C) Results in A quantified for the whole brain (t = 2.50, df = 15, P = 0.025, n = 8 or 9 per group) (B) and for the hippocampus (t = 2.17, df = 15, P = 0.047, n = 8 or 9 per group) (C). (D–F) Hippocampal membrane protein levels were reduced for GluT1 (t = 2.45, df = 9.2, P = 0.036) (D) but not for GluT3 (t = 0.94, df = 15, P = 0.40) (E) or GluT4 (t = 0.66, df = 14, P = 0.52) (F). Data are presented as mean + SEM; *P < 0.05, Student’s t test in B–D.CC BY-NC-ND · PubMed Central
Fig. 5. EMPA treatment impedes CSD-induced disturbances in glucose metabolism and rescues spatial memory for H-Gluc mice but is detrimental to Int-Gluc animals. (A) In control animals, EMPA reduced peripheral glucose (t = 3.01, df = 30, P = 0.005; vehicle-treated control mice, n = 10; EMPA-treated control mice, n = 22). (B) EMPA-treated control mice were classified as H-Gluc (>150 mg/dL), Int-Gluc (125–150 mg/dL), or L-Gluc (<125 mg/dL) based on peripheral blood glucose values (mean ± SD) of vehicle-treated control mice. (C) In the Y-maze, vehicle-treated control mice and EMPA-treated control Int-Gluc mice showed intact novel arm preference, whereas EMPA-treated control L-Gluc mice did not reveal a preference (against chance for control vehicle-treated mice: t = 3.03, df = 9, P = 0.014; for EMPA-treated control L-Gluc mice: t = 0.77, df = 8, P = 0.46; and for EMPA-treated control Int-Gluc mice: t = 3.55, df = 12, P = 0.004; n = 9–13 per group). (D) CSD-exposed mice displayed increased blood glucose levels compared with control mice 2 d post-CSD (t = 3.00, df = 64, P = 0.004, n = 19 and 47 per group, respectively) and were classified into H-Gluc, Int-Gluc, and L-Gluc groups. (E) Glucose was detected in the urine of EMPA-treated mice only [treatment: F(1,20) = 59.51, P < 0.001, n = 5–7 per group; Int-Gluc: t = 5.81, df = 20, P < 0.001; H-Gluc: t = 5.14, df = 20, P < 0.001]. (F) In the Y-maze, EMPA treatment worsened the performance of the CSD/Int-Gluc group compared with the vehicle-treated CSD/Int-Gluc group [interaction: F(1,42) = 23.24, P < 0.001, n = 8–15 per group; Int-Gluc: t = 4.08, df = 42, P < 0.001]. In contrast, vehicle-treated CSD/H-Gluc mice did not show a novel arm preference, but EMPA treatment of CSD/H-Gluc mice rescued these spatial memory impairments (H-Gluc: t = 2.95, df = 42, P < 0.05). (G) In vehicle-treated CSD mice Y-maze performance correlated negatively with peripheral glucose levels 2 d post-CSD (r = −0.56, r2 = 0.31, P = 0.005). (H) In contrast, for EMPA-treated CSD mice, Y-maze performance correlated positively with peripheral glucose levels 2 d post-CSD (r = 0.44, r2 = 0.19, P = 0.03). (I) In the GTT performed 3 wk post-CSD vehicle-treated CSD/H-Gluc mice showed impaired glucose metabolism, which was normalized for EMPA-treated CSD/H-Gluc mice [interaction: F(12,80) = 3.78, P < 0.001; time: F(4,80) = 85.26; P < 0.001; treatment: F(3,20) = 17.82, P < 0.001; n = 5–9 per group]. For significant effects at 30 min, vehicle-treated CSD/Int-Gluc mice vs. EMPA-treated mice CSD/Int-Gluc: t = 2.91, df = 100, P < 0.05; in vehicle-treated CSD/H-Gluc mice vs. EMPA-treated CSD/H-Gluc mice: t = 6.74, df = 100, P < 0.001; in vehicle-treated CSD/Int-Gluc mice vs. vehicle-treated CSD/H-Gluc mice: t = 5.80, df = 100, P < 0.001; and for significant effects at 60 min, in vehicle-treated CSD/H-Gluc mice vs. EMPA-treated mice CSD/H-Gluc mice: t = 4.27, df = 100, P < 0.001; in vehicle-treated CSD/Int-Gluc mice vs. vehicle-treated mice CSD/H-Gluc mice: t = 2.89, df = 100, P < 0.05. Data are presented as mean ± SEM in A, C, E, F, and I and as mean ± SD in B and D; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test in A and D, one-sample t test against chance in C and F, two-way ANOVA with Bonferroni’s posttest in E, F, and I, or Pearson’s correlation coefficient in G and H; the regression lines are shown with the 95% confidence interval (dotted lines).
Fig. 5. EMPA treatment impedes CSD-induced disturbances in glucose metabolism and rescues spatial memory for H-Gluc mice but is detrimental to Int-Gluc animals. (A) In control animals, EMPA reduced peripheral glucose (t = 3.01, df = 30, P = 0.005; vehicle-treated control mice, n = 10; EMPA-treated control mice, n = 22). (B) EMPA-treated control mice were classified as H-Gluc (>150 mg/dL), Int-Gluc (125–150 mg/dL), or L-Gluc (<125 mg/dL) based on peripheral blood glucose values (mean ± SD) of vehicle-treated control mice. (C) In the Y-maze, vehicle-treated control mice and EMPA-treated control Int-Gluc mice showed intact novel arm preference, whereas EMPA-treated control L-Gluc mice did not reveal a preference (against chance for control vehicle-treated mice: t = 3.03, df = 9, P = 0.014; for EMPA-treated control L-Gluc mice: t = 0.77, df = 8, P = 0.46; and for EMPA-treated control Int-Gluc mice: t = 3.55, df = 12, P = 0.004; n = 9–13 per group). (D) CSD-exposed mice displayed increased blood glucose levels compared with control mice 2 d post-CSD (t = 3.00, df = 64, P = 0.004, n = 19 and 47 per group, respectively) and were classified into H-Gluc, Int-Gluc, and L-Gluc groups. (E) Glucose was detected in the urine of EMPA-treated mice only [treatment: F(1,20) = 59.51, P < 0.001, n = 5–7 per group; Int-Gluc: t = 5.81, df = 20, P < 0.001; H-Gluc: t = 5.14, df = 20, P < 0.001]. (F) In the Y-maze, EMPA treatment worsened the performance of the CSD/Int-Gluc group compared with the vehicle-treated CSD/Int-Gluc group [interaction: F(1,42) = 23.24, P < 0.001, n = 8–15 per group; Int-Gluc: t = 4.08, df = 42, P < 0.001]. In contrast, vehicle-treated CSD/H-Gluc mice did not show a novel arm preference, but EMPA treatment of CSD/H-Gluc mice rescued these spatial memory impairments (H-Gluc: t = 2.95, df = 42, P < 0.05). (G) In vehicle-treated CSD mice Y-maze performance correlated negatively with peripheral glucose levels 2 d post-CSD (r = −0.56, r2 = 0.31, P = 0.005). (H) In contrast, for EMPA-treated CSD mice, Y-maze performance correlated positively with peripheral glucose levels 2 d post-CSD (r = 0.44, r2 = 0.19, P = 0.03). (I) In the GTT performed 3 wk post-CSD vehicle-treated CSD/H-Gluc mice showed impaired glucose metabolism, which was normalized for EMPA-treated CSD/H-Gluc mice [interaction: F(12,80) = 3.78, P < 0.001; time: F(4,80) = 85.26; P < 0.001; treatment: F(3,20) = 17.82, P < 0.001; n = 5–9 per group]. For significant effects at 30 min, vehicle-treated CSD/Int-Gluc mice vs. EMPA-treated mice CSD/Int-Gluc: t = 2.91, df = 100, P < 0.05; in vehicle-treated CSD/H-Gluc mice vs. EMPA-treated CSD/H-Gluc mice: t = 6.74, df = 100, P < 0.001; in vehicle-treated CSD/Int-Gluc mice vs. vehicle-treated CSD/H-Gluc mice: t = 5.80, df = 100, P < 0.001; and for significant effects at 60 min, in vehicle-treated CSD/H-Gluc mice vs. EMPA-treated mice CSD/H-Gluc mice: t = 4.27, df = 100, P < 0.001; in vehicle-treated CSD/Int-Gluc mice vs. vehicle-treated mice CSD/H-Gluc mice: t = 2.89, df = 100, P < 0.05. Data are presented as mean ± SEM in A, C, E, F, and I and as mean ± SD in B and D; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test in A and D, one-sample t test against chance in C and F, two-way ANOVA with Bonferroni’s posttest in E, F, and I, or Pearson’s correlation coefficient in G and H; the regression lines are shown with the 95% confidence interval (dotted lines).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Research works printed but not linked: 2

  1. F Erbsloh, A Bernsmeier, H Hillesheim, [The glucose consumption of the brain & its dependence on the liver]. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 196, 611–626. German (1958).
  2. 10.1210/endo.130.1.1727703 · doi:10.1210/endo.130.1.1727703 · Paper page

Cited by

See all 92

Metadata

Authors
van der Kooij, M. A., Jene, T., Treccani, G., Miederer, I., Hasch, A., Voelxen, N., Walenta, S., & Müller, M. B.
Affiliations
  • Translational Psychiatry, Department of Psychiatry, Psychotherapy and Focus Program Translational Neurosciences, University Medical Center, Johannes Gutenberg University Mainz, 55128 Mainz, Germany;
  • Johannes Gutenberg University Mainz (DE)
Venue
Proceedings of the National Academy of Sciences
Published
2018-10-09
Volume
115
Issue
43
Pages
E10187-E10196
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2895951954
Cited by
92
References
77
Citations by year
2026: 7 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 15 · 2021: 12 · 2020: 17 · 2019: 5
FWCI
4.88
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by-nc-nd)
Funders
Danish Council (DFF-5053-00103)
Topics
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
chronic social defeat stress, hyperglycemia, stress vulnerability, spatial memory, hippocampus, brain glucose metabolism, glucose homeostasis, empagliflozin, SGLT2 inhibitors, stress resilience, depression, diabetes comorbidity, cognitive impairment
MeSH terms
Animals, Behavior, Animal, Benzhydryl Compounds, Brain, Chronic Disease, Glucose, Glucosides, Hyperglycemia, Male, Memory Disorders, Mice, Inbred C57BL, Social Desirability, Stress, Psychological, Mice, Spatial Memory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic social stress-induced hyperglycemia in mice couples individual stress susceptibility to impaired spatial memory. https://app.cochat.ai/papers/10.1073/pnas.1804412115
The paper
van der Kooij, M. A., Jene, T., Treccani, G., Miederer, I., Hasch, A., Voelxen, N., Walenta, S., & Müller, M. B. (2018). Chronic social stress-induced hyperglycemia in mice couples individual stress susceptibility to impaired spatial memory. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1804412115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.